Aurobindo Pharma plans new growth strategies
Aurobindo Pharma would broaden product portfolio in the US while entering new markets in Europe as part of its growth strategy over the next 3-4 years. In the US, it plans to broaden portfolio through accelerated growth in injectable, OTC and higher complexity products. On the other hand, in Europe, the company is planning to expand presence into new geographies such as Poland and Czech Republic besides enhancing its position in existing countries such as France, Germany, Netherlands, Spain and the UK. Aurobindo has been following a strategy of differentiated pipeline with new launches, including injectables, ophthalmics, speciality products and controlled substances in the US market. Moreover, it has also expanded presence in dietary supplement business through Natrol, which it had acquired in 2014. The company had posted consolidated net revenue from operations of Rs 3,678.7 crore for the first quarter ended June 30, 2017-18. Out of this the US formulation sales were at Rs 1,694.9 crore and Europe formulations sales were at Rs 917.6 crore.